BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

Gautam BorthakurYishai OfranMartin S TallmanJames M ForanGeoffrey L UyJohn F DiPersioMargaret M ShowelAvichai ShimoniArnon NaglerJacob M RoweJessica K AltmanMichal AbrahamAmnon PeledStephen ShawOsnat Bohana-KashtanElla SoraniYaron PeregAdam Foley-ComerGalia OberkovitzTzipi M LustigIrit Glicko-KabirArnon AharonAbi Vainstein-HarasShaul E KadoshEmil SamaraAhmed N Al-RawiNaveen PemmarajuCarlos Bueso-RamosJorge E CortesMichael Andreeff

Published in: Cancer (2020)

The current results demonstrate the efficacy of CXCR4 targeting with BL-8040 and support continued clinical development in acute myelogenous leukemia.

Keyphrases

acute myeloid leukemia
liver failure
respiratory failure
bone marrow
drug induced
aortic dissection
acute lymphoblastic leukemia
cell migration
diffuse large b cell lymphoma
multiple myeloma
cancer therapy
hepatitis b virus
hodgkin lymphoma
extracorporeal membrane oxygenation
acute respiratory distress syndrome